Cannabis Bioscience International Holdings (CBIH) Announces SEC Approval for Common Stock Sale
LOS ANGELES- Cannabis Bioscience International Holdings (CBIH), a prominent player in the cannabis bioscience sector, announced on Friday a significant milestone in its financial journey. The company’s registration statement on Form S-1, under the Securities Act of 1933, was declared effective by the United States Securities and Exchange Commission (SEC) on December 5.
This pivotal move allows CBIH to proceed with the registration of 10,087,154,885 shares of its common stock, priced at $0.0008 per share. Of these, 6.25 billion shares are being offered directly by Cannabis Bioscience, while the remaining 3,837,154,885 shares may be available through selling stockholders, as detailed in a recent press release.
Dr. Jose Torres, MD, the medical director at the Houston, Texas-based Cannabis Bioscience, expressed gratitude for the local support in Texas, acknowledging the role of the community in reaching this achievement. “Texans’ hard work, perseverance and healthy disregard for the impossible have undoubtedly paid off,” he said.
Cannabis Bioscience, known for its comprehensive services in all therapeutic areas of clinical research, plans to utilize the proceeds from this stock offering to launch cannabis clinical trials. These trials will leverage AI programs to enhance research efficiency, reflecting the company’s innovative approach in the field.
Henry Levinski, CBIH’s treasurer and vice president, emphasized the significance of clinical research in advancing medicinal cannabis treatments. “Clinical research is the cornerstone of medicinal treatments and the ultimate push for patients to consider cannabinoid therapies their first option, not their last resource,” he stated.
Previously, Cannabis Bioscience has collaborated with notable industry names such as BioIVT, Phillips Morris, Pfizer, and Inventiva, showcasing its established presence in the sector.
This development comes in the wake of sustained efforts by cannabis activists in Texas to promote reform, following legislative setbacks. It also aligns with a growing interest in cannabis stocks, which experts believe are now positioned for substantial growth after finding their market base.